UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice maintains a Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $137 to $150.
May 01, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst A.J. Rice maintains a Buy rating on Tenet Healthcare and raises the price target from $137 to $150.
The increase in price target by UBS suggests a positive outlook on Tenet Healthcare's future performance, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100